The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.

"Declarations Ethics approval and consent to particpateThis study was conducted according to the guidelines of the declaration of Helsinki and has been approved by the regional ethics committee of Karolinska Institutet (approval ID: 1126). The work follows the 2010/63/EU directive and is reported according to the ARRIVE guidelines [114]. Consent for publicationAll authors have declared their consent for this publication. Competing interestsThis study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG. TK is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. T.N. has received unrestricted grants from AstraZeneca and consultancy fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Merck and Sanofi-Aventis. The other authors declare that they have no competing interests. Competing interests This study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG. TK is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. T.N. has received unrestricted grants from AstraZeneca and consultancy fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Merck and Sanofi-Aventis. The other authors declare that they have no competing interests."

"Funding Open access funding provided by Karolinska Institute. Financial support was provided by the Swedish Medical Research Council (2022-00577 to CP), The FANG Foundation and Hjärnfonden/The Swedish Brain Foundation (CP), the Swedish Heart–Lung Foundation (TN), Ulla Hamberg Angeby och Lennart Angebys Stiftelse (VD and EV), the Swedish Stroke Foundation (VD and EV), Foundation for Geriatric Diseases at Karolinska Institutet (EV), ALF Stockholm (951953 to TN)."